(Reuters Breakingviews) - Rampaging animal spirits have given birth to a biotechnology unicorn. It's apt that a stellar year for initial public offerings in the sector will be capped by its biggest float ever. Juno Therapeutics is a year old and revenue free, but its cancer fighting technology is hot. At nearly a $2 billion valuation, the company shows capitalism's ability to catalyze investors' hopes and resources.
image: http://www.freedigitalphotos.net
